Replies to post #323616 on Avid Bioservices Inc (CDMO)

[revenue_monster]

residual value.

[JamesGMS]

Great find hutschi,

Dulling cancer therapy’s double-edged sword: A new way to block tumor recurrence

https://vector.childrenshospital.org/2018/01/resolvins-block-cancer-recurrence/

Hmmmm.......PS.....no value.......hahaha.......IMO

Hahaha indeed : ) Just confirms what those in the know have been saying for years now - Most important quotes below:

In their study, published in the January issue of the Journal of Experimental Medicine, the researchers describe how chemotherapy or other targeted therapies create a build-up of tumor cell debris, comprised of dead, fragmented cancer cells.

In animal models, the team observed that this cell debris sets off an inflammatory cascade in the body and also encourages lingering, living cancer cells to develop into new tumors.

Strikingly, they saw that the co-mingling of debris and living tumors cells resulted in 100 times more accelerated tumor growth.

And the culprit? A particular molecule — named phosphatidylserine — that appears during the cell death process that remains exposed on the dead cell fragments.

Gee, what if you had something that could cover up the PS??
Anyone heard of anything promising in this regard?? : )

Once detected by the immune system, phosphatidylserine sets off a flood of pro-inflammatory activity, creating the perfect storm for unfettered tumor growth from cancer cells that evaded initial drugging.

These tumors are then resistant to further chemotherapy.

I think Lias will soon be able to respond appropriately to those "difficult issues" he's had so much trouble with.

Have a nice afternoon.

James

[north40000]

Thanks hutschi. IMO, an email with a link to the article should be

addressed to the MSKCC authors of recent posters presented at 2016 and

2017 SITC and 2017 AACR, e.g. 2017 AACR poster #1651. Drs Jedd Wolchok,

Taha Merghoub, Sadna Budhu, Daniel Hirschhorn-Cymerman should suffice.

Also, [e-mail] or [e-mail].


It could be that Dr. Lias does not read all journals not in CDMO field,

particularly Journal of Experimental Medicine. [e-mail].

[swg_tdr]

Bavi=residual. “Resolvins are already in advanced clinical trials for a number of inflammatory diseases and can be rapidly translated to the oncology population,” Kieran says.

This work was supported by the National Cancer Institute etc